Alterity Therapeutics (ATH) Q4 2025 TU earnings summary

Executive summary

• Granted U.S. FDA Fast Track Designation for ATH434 to treat Multiple System Atrophy (MSA), highlighting regulatory progress and recognition of unmet need.

• Reported positive topline data from both double-blind and open-label Phase 2 clinical trials of ATH434 in MSA, showing clinical benefit and robust efficacy.

• Presented additional analyses and neuroimaging data demonstrating slowed disease progression, improved symptoms, and favorable safety profile for ATH434.

Financial highlights

• Cash balance at 30 June 2025 was A$40.66M, up from A$17.96M at the previous quarter end.

• Operating cash outflows for the quarter were A$2.35M, with year-to-date outflows of A$11.45M.

• Raised A$26.3M in gross proceeds from the completion of a two-tranche placement during the quarter.

• Received A$3.98M refund from the Australian Taxation Office under the R&D Tax Incentive Scheme.

• Estimated 17.3 quarters of funding available based on current cash and burn rate.

Outlook and guidance

• Preparing for further interactions with the U.S. FDA following Fast Track designation and positive clinical data.

• Continued advancement of ATH434 for MSA supported by consistent efficacy and safety data across trials.